A Case to Support the Continued Use of Rifampin in Clinical Drug-Drug Interaction Studies

Affiliations

• ¹ Gilead Sciences, Inc., Nonclinical Safety and Pathobiology (NSP), Foster City, California, USA.
• ² Lhasa Limited, Leeds, UK.
• ³ Pharmacokinetics, Dynamics & Metabolism, Pfizer Research & Development, Groton, Connecticut, USA.
• ⁴ Drug Safety Research and Development, Pfizer Research & Development, Groton, Connecticut, USA.
• ⁵ Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA.
• ⁶ Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.